DiaGenic to Partner with Opaldia in UK on Blood Based Breast Cancer Gene Expression Test.Strategic collaboration ensures rapid availability in pivotal UK market OSLO, Norway -- The Norwegian life sciences company, DiaGenic ASA Asa (ā`sə), in the Bible, king of Judah, son and successor of Abijah. He was a good king, zealous in his extirpation of idols. When Baasha of Israel took Ramah (a few miles N of Jerusalem), Asa bought the help of Benhadad of Damascus and today announced that it has signed a letter of intent with Opaldia concerning Opaldia becoming the commercial partner in the UK for its proprietary gene expression tests. The first is expected to be DiaGenic's breast cancer test, which is aiming for CE mark approval by the end of 2008. The test will be made available in the UK to private patients as part of the Opaldia Breastcare Programme. The agreement between DiaGenic and Opaldia also includes the use of the research-use-only (RUO RUO Research Use Only RUO Reference Unbundling Offer RUO Run Ultima Online (emulator program) RUO Resident Unit Officer ) version of the test in studies funded by Opaldia until a CE approved version is available. Dr James Mackay There have been six notable people named James Mackay.
adj. 1. Of, relating to, or useful in prognosis. 2. Of or relating to prediction; predictive. n. 1. A sign or symptom indicating the future course of a disease. 2. assay, and inclusion of the DiaGenic test in our programme will demonstrate our nationwide leading position as a provider of advanced genetics within the oncology field." Dr Erik Christensen Not to be confused with Erika Christensen. Erik Christensen (Born on December 17, 1983 in Edmonton, Alberta) is a current NHL hockey player for the Pittsburgh Penguins. , CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of DiaGenic comments: "We are very pleased and looking forward to this partnership with Opaldia. This will be our first commercial agreement providing market access in the UK through a highly competent organization with broad experience in bringing new diagnostic technologies to the market." About DiaGenic ASA DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood peripheral blood Cardiology Blood circulating in the system/body . This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts. Significant potential in numerous diseases such as breast cancer and Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. has been identified. The company has been granted patents in the U.S. and Europe. DiaGenic is listed on the Oslo Stock Exchange Oslo Stock Exchange An exchange founded in 1819 and trading stocks, bonds, and stock options that is considered the options market of Norway. . For more information visit www.diagenic.com About Opaldia Opaldia is a private healthcare provider which aims to provide a lifelong breast cancer service to its members. All its services are offered in independent hospitals by consultant grade oncologists. Other gene expression tests offered by the company in the breast cancer field are: MammaPrint - for disease prognosis; and CupPrint, which identifies the origin of mestasized tumours. For more information please visit the www.opaldia.com or contact Dr James Mackay, Opaldia, +44 20-7554 4045; james.mackay@opaldia.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion